By ONN Staff

A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.

Daraxonrasib, tarlatamab, an mRNA melanoma therapy and ivonescimab led ESMO 2026. Tell us which findings you can act on now.

At an Oncology Nursing News roundtable, APPs discussed earlier lifileucel referral, IL-2 dosing, and toxicities that emerge after discharge.

Leslie Smith, DNP, shares how nurses at any hospital can work around limited time, heavy workloads, and slow approvals to get involved in research.

At an ONN Case-Based Roundtable, APPs discussed when to raise TIL therapy in melanoma and how to prepare patients for lymphodepletion and IL-2.

An NP-led roundtable reviewed 3L+ trial data in metastatic colorectal cancer and shared nursing strategies for myelosuppression, dosing, and goals.

New ANA guidance sets shared duties for nurses, leaders, and educators and favors restorative responses over zero-tolerance policies.

In TALAPRO-3, adding talazoparib to enzalutamide cut the risk of radiographic progression or death by 52%; anemia was the leading toxicity.

Divarasib beat first-generation KRAS G12C inhibitors in NSCLC, while new data on olomorasib, daraxonrasib, and a KRAS G12D inhibitor expand the field.

Stepped care for fear of cancer recurrence was rated feasible by most clinicians, while training all staff to screen was rated least feasible.

The approval covers IV and subcutaneous pembrolizumab and raises the TMB-H threshold from 10 to 13 mutations/megabase.

The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after platinum-based chemotherapy.

Leslie Smith, DNP, discusses mediating trial care, vetting protocols for nursing scope of practice, and guiding frontline nurses toward research.

ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.

Long-term QUILT-3.032 data in BCG-unresponsive NMIBC with CIS show durable responses for some patients and a long, surveillance-heavy course.

The approval in stage II/III MSI-H/dMMR rectal cancer rests on AZUR-1, in which 71% of patients needed no treatment beyond dostarlimab.

Life table analysis estimates residual ovarian cancer risk by current age and planned age at risk-reducing surgery.

Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS efficacy data.

Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.

Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.

FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.

Five-week hypofractionated radiation after prostatectomy showed similar 5-year cancer control and quality of life but more grade 3 urinary toxicity.

FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.

Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175.

Solid tumor history, cardiopulmonary symptom burden, and age-dependent chemo intensity predicted 30-day readmission or death after AML induction.

Take our quick survey to help Oncology Nursing News improve how we deliver updates across web, video, email, social media, and podcasts.

An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology nursing takeaways.

FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.

From ICN 2026, Heather Jackson and Ashley Johnson detail APP breast care access models, global cancer pain barriers, and burnout mitigation tactics.

FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.